FDA’s decision to approve new treatment for Alzheimer’s disease

Local News

Wis. (WLAX/WEUX) – For the first time since 2003, there will be another pharmaceutical option to treat Alzheimer’s disease.

Aducanumab would be for those who have been diagnosed with mild cognitive issues stemming from the disease. This drug would not be a cure and is meant to slow the effects of Alzheimer’s.

Nathanial chin of the Wisconsin Alzheimer’s disease and research centers says the drug attaches itself to a protein in the brain that can slow the disease.

“To this protein call amyloid. This is a significant protein because it is the first of two proteins that make up Alzheimer’s disease and this drug removes that protein from the brain,”

The new drug is still in clinical stages of testing and is not yet available by prescription.

Dr. Chin believes that will change in a few months.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trending Stories

Don't Miss

Community Calendar